Theravance Biopharma (TBPH) Free Cash Flow Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 24.91% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 20.11% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.71% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -10.65% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 31.42% |
| 10 | Theravance Biopharma | 823.54 Mn | 428.87 Mn | - | 100.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 100.22% |
| Dec 31, 2025 | 63.45% |
| Sep 30, 2025 | 33.84% |
| Jun 30, 2025 | 154.04% |
| Mar 31, 2025 | 53.76% |
| Dec 31, 2024 | 70.58% |
| Sep 30, 2024 | 51.78% |
| Jun 30, 2024 | 55.43% |
| Mar 31, 2024 | 75.05% |
| Dec 31, 2023 | 71.50% |
| Sep 30, 2023 | 68.35% |
| Jun 30, 2023 | 37.98% |
| Mar 31, 2023 | 39.92% |
| Dec 31, 2022 | -23.72% |
| Sep 30, 2022 | 20.49% |
| Jun 30, 2022 | 33.25% |
| Mar 31, 2022 | 31.65% |
| Dec 31, 2021 | 7.21% |
| Sep 30, 2021 | 2.95% |
| Jun 30, 2021 | 7.07% |
| Mar 31, 2021 | -52.15% |
| Dec 31, 2020 | -14.18% |
| Sep 30, 2020 | -7.80% |
| Jun 30, 2020 | -7.17% |
| Mar 31, 2020 | -3.46% |
| Dec 31, 2019 | -32.05% |
| Sep 30, 2019 | -51.54% |
| Jun 30, 2019 | -14.04% |
| Mar 31, 2019 | -45.07% |
| Dec 31, 2018 | -16.04% |
| Sep 30, 2018 | -15.91% |
| Jun 30, 2018 | -9.79% |
| Mar 31, 2018 | 41.33% |
| Dec 31, 2017 | -0.88% |
| Sep 30, 2017 | -19.67% |
| Jun 30, 2017 | 4.34% |
| Mar 31, 2017 | -2.93% |
| Dec 31, 2016 | 7.69% |
| Sep 30, 2016 | 27.11% |
| Jun 30, 2016 | -9.39% |
| Mar 31, 2016 | 2.62% |